CTLA4 and melanoma: Given these findings and the parallels in toxicity for monotherapy between adjuvant treatment of stage III/IV and stage IIB/IIC disease, combination adjuvant immunotherapy with anti-CTLA4 and anti-PD1 therapy may have an acceptable toxicity profile in the adjuvant space in the lower risk stage II melanoma setting.